Related Experiment Video
Updated: Aug 11, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Myelotoxicity from chemotherapy
Davey Daniel1, Jeffrey Crawford
1Department of Hematology-Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain.
Related Concept Videos
Drugs that Destabilize Microtubules
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Secondary Spinal Cord Injury llI: Pathophysiology
Treatment Resistant Cancers